Related Experiment Videos
Systemic therapy of malignant melanoma
1Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden.
Medical Oncology (Northwood, London, England)
|June 1, 1997
Summary
Current malignant melanoma treatments offer limited success for disseminated disease. Adjuvant interferon therapy shows promise for high-risk patients, but new biologic therapies are on the horizon.
Area of Science:
- Oncology
- Medical treatment of malignant melanoma
Background:
- Malignant melanoma, particularly disseminated forms, remains largely incurable.
- Current single-agent chemotherapy offers modest, short-term remission for few patients.
Purpose of the Study:
- To review the current medical treatment status for malignant melanoma.
- To discuss adjuvant therapy for high-risk melanoma and treatment for disseminated disease.
Main Methods:
- Review of current therapeutic strategies for malignant melanoma.
- Discussion of chemotherapy, cytokine combinations, and interferon-alpha 2b therapy.
- Exploration of emerging molecular and immunological treatment approaches.
Main Results:
- Combination chemotherapy and cytokine therapy increase response rates but not survival.
- Adjuvant interferon-alpha 2b therapy significantly improves survival in high-risk melanoma patients, despite toxicity.
- New insights into drug resistance may enable predictive tests and resistance-circumventing strategies.
Conclusions:
- Disseminated malignant melanoma is largely incurable with current therapies.
- Adjuvant interferon therapy represents a significant advancement for high-risk melanoma.
- Future treatments may involve novel vaccines and biologic therapies based on molecular and immunological advances.